[Complete Response Achieved by Gemcitabine+Cisplatin+Durvalumab Therapy for Lymph Node Recurrence of Intraductal Cholangiocarcinoma-A Case Report].

The prognosis for unresectable or recurrent biliary tract cancer is generally unfavorable. However, recent reports suggest that combination therapy with immune checkpoint inhibitors may improve outcomes. We report the case of a 79-year-old woman with intrahepatic cholangiocarcinoma who underwent radical resection. Three months post-surgery, she developed a recurrence in an intra-abdominal lymph node. Treatment with 4 courses of gemcitabine+cisplatin+durvalumab(GCD)resulted in a complete response, with no measurable lesions detected on imaging. The patient continued treatment and was subsequently transitioned to durvalumab monotherapy. Although treatment was discontinued due to drug-induced pneumonia, she has remained relapse-free since. To our knowledge, this is the first reported case of a complete response to GCD therapy in biliary tract cancer.